FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	DC	20549
vasimigion,	D.O.	20070

STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average to	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

Name and Address of Reporting Person* Squarer Ron				De	2. Issuer Name and Ticker or Trading Symbol Deciphera Pharmaceuticals, Inc. [DCPH]							(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(Fi	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/16/2024							Officer below)	(give title		Other (sp below)	pecify	
C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person							
(Street)	AM M	A	02451											Form f Persor	iled by More	e than On	e Report	ing
(City)	(SI	ate)	(Zip)		- Ru 	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						to						
		Tab	le I - Noi	n-Deriv	vative	e Se	curitie	s A	cquire	l, Di	sposed	of, or Be	neficia	ly Owned	l			
1. Title of Security (Instr. 3) 2. Transa Date (Month/Di				Execution Date,		Code	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			Beneficia Owned F	es ally following	6. Owner Form: Dir (D) or Ind (I) (Instr.	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	(A) or (D) Price		Reported Transact (Instr. 3	ion(s)		"	Instr. 4)		
		7	Table II -						. ,			f, or Ben ible sec		Owned				
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ow For Dir or (I)	vnership rm: ect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$14.46	01/16/2024			A		4,727		(1)		01/15/2034	Common Stock	4,727	\$10.5783 ⁽¹⁾	4,727		D	

Explanation of Responses:

1. These options were issued upon election by the director to receive his cash board retainer fee of \$50,000 for the FY 2024 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024.

/s/ Jeffrey M. Held, Attorney-

01/18/2024

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.